These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10097686)

  • 41. In vitro activity of tigecycline against Bacteroides species.
    Betriu C; Culebras E; Gómez M; Rodríguez-Avial I; Picazo JJ
    J Antimicrob Chemother; 2005 Aug; 56(2):349-52. PubMed ID: 15951353
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).
    Snydman DR; Jacobus NV; McDermott LA; Golan Y; Hecht DW; Goldstein EJ; Harrell L; Jenkins S; Newton D; Pierson C; Rihs JD; Yu VL; Venezia R; Finegold SM; Rosenblatt JE; Gorbach SL
    Clin Infect Dis; 2010 Jan; 50 Suppl 1():S26-33. PubMed ID: 20067390
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.
    Cuchural GJ; Tally FP; Jacobus NV; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C
    Antimicrob Agents Chemother; 1990 Mar; 34(3):479-80. PubMed ID: 2334161
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mechanisms of resistance in anaerobes and new developments in testing.
    Finegold SM
    Diagn Microbiol Infect Dis; 1989; 12(4 Suppl):117S-120S. PubMed ID: 2686914
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinico-microbiological profile of
    Gupta A; Shenoy PA; Kumar A; Chawla K
    Indian J Med Res; 2021 May; 154(5):750-756. PubMed ID: 35532593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antibiotic sensitivity of Bacteroides fragilis group in Algeria].
    Merad AS; Ghemati M; Faid N; Kimouche N
    Arch Inst Pasteur Alger; 1998; 62():91-110. PubMed ID: 11256322
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation.
    Cuchural GJ; Tally FP; Jacobus NV; Aldridge K; Cleary T; Finegold SM; Hill G; Iannini P; O'Keefe JP; Pierson C
    Antimicrob Agents Chemother; 1988 May; 32(5):717-22. PubMed ID: 3395102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic resistance in anaerobic bacteria.
    Tally FP; Cuchural GJ
    J Antimicrob Chemother; 1988 Jul; 22 Suppl A():63-71. PubMed ID: 3264832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada.
    Labbé AC; Bourgault AM; Vincelette J; Turgeon PL; Lamothe F
    Antimicrob Agents Chemother; 1999 Oct; 43(10):2517-9. PubMed ID: 10508035
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bacteroides, Prevotella, and Porphyromonas species: a review of antibiotic resistance and therapeutic options.
    Falagas ME; Siakavellas E
    Int J Antimicrob Agents; 2000 Jun; 15(1):1-9. PubMed ID: 10856670
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bacteroides fragilis: current susceptibilities, mechanisms of drug resistance, and principles of antimicrobial therapy.
    Cuchural GJ; Tally FP
    Drug Intell Clin Pharm; 1986; 20(7-8):567-73. PubMed ID: 3488895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.
    Lee Y; Park Y; Kim MS; Yong D; Jeong SH; Lee K; Chong Y
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3993-7. PubMed ID: 20585132
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-lactamase-mediated imipenem resistance in Bacteroides fragilis.
    Cuchural GJ; Malamy MH; Tally FP
    Antimicrob Agents Chemother; 1986 Nov; 30(5):645-8. PubMed ID: 3492173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antimicrobial effect of beta-lactam antibiotic combinations against Bacteroides fragilis in vitro.
    Bansal MB; Thadepalli H
    Antimicrob Agents Chemother; 1983 Jan; 23(1):166-8. PubMed ID: 6830206
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cefoxitin inactivation by Bacteroides fragilis.
    Cuchural GJ; Tally FP; Jacobus NV; Marsh PK; Mayhew JW
    Antimicrob Agents Chemother; 1983 Dec; 24(6):936-40. PubMed ID: 6660860
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antimicrobial Resistance Profile and
    Vishwanath S; Shenoy PA; Chawla K
    J Glob Infect Dis; 2019; 11(2):59-62. PubMed ID: 31198308
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Enhanced antimicrobial activity of old and new beta-lactams against cefoxitin-resistant Bacteroides fragilis group isolates by beta-lactamase inhibitors.
    Aldridge KE; Henderberg A; Sanders CV
    J Antimicrob Chemother; 1990 May; 25(5):873-5. PubMed ID: 2373670
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of intraabdominal infection.
    Gorbach SL
    Am J Med; 1984 May; 76(5A):107-10. PubMed ID: 6372458
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Surveillance of Antimicrobial Susceptibility of Anaerobe Clinical Isolates in Southeast Austria:
    König E; Ziegler HP; Tribus J; Grisold AJ; Feierl G; Leitner E
    Antibiotics (Basel); 2021 Apr; 10(5):. PubMed ID: 33919239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibiotic levels in infected and sterile subcutaneous abscesses in mice.
    Joiner KA; Lowe BR; Dzink JL; Bartlett JG
    J Infect Dis; 1981 Mar; 143(3):487-94. PubMed ID: 6453169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.